Navigation Links
Promise in Medical Technology

New Study Using Combination of Bioengineered Skin and Stem Cells Shows Promise in Treatment of Non-Healing Wounds

SAN FRANCISCO, March 5 /PRNewswire-USNewswire/ -- Scleroderma is an autoimmune disease that leads to thickening and severe scarring of skin as well as thickening and failure of internal organs, including the lungs, heart, kidneys and intestines. The disease -- which the Scleroderma Foundation esti...

Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study

Results of NIH-sponsored Clinical Trial to be Presented at Retrovirus Conference LEXINGTON, Mass., Feb. 9 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV ) announced today that a National Institutes of Health (NIH)-sponsored clinical study found that participating wome...

Novel Compound Shows Promise for Treatment of Alcoholism

BIRMINGHAM, Ala., Sept. 11 /PRNewswire-USNewswire/ --- Southern Research Institute and Gallo Research Center today announced that peer-reviewed results from a study testing Naltrexone-derived pyridomorphinan (SoRI-9409) will be published in the December 2008 issue of the journal Biological Psy...

New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis

The American College of Rheumatology Research and Education Foundation's Within Our Reach Campaign Yields Significant Advances in Detecting, Treating and Understanding RA ATLANTA, Sept. 3 /PRNewswire/ -- For the first time during its unprecedented initiative to find a cure...

Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show Promise for Early Detection of Alzheimer's

CHICAGO, July 29 /PRNewswire-USNewswire/ -- With the continued aging of the population and the growing epidemic of Alzheimer's, early detection of the disease is crucial for risk assessment, testing new therapies, and eventual early intervention with better drugs, once they are developed. Four...

Device Blocking Stomach Nerve Signals Shows Promise in Obesity

ROCHESTER, Minn., June 26 /PRNewswire-USNewswire/ -- A new implantable medical device, developed in collaboration with Mayo Clinic researchers, shows promise as a reversible and less extreme alternative to existing bariatric surgeries, according to findings published in the current issue of th...

Blueberry-Supplemented Diet Shows Promise in Lowering Cholesterol in Animal Trials

PORTLAND, Maine, June 19 /PRNewswire/ -- New research published in the British Journal of Nutrition (Br J Nutr., Dec. 17, PMID: 18081945, 2007) shows that blueberries may have a cardio-protective effect, by significantly lowering cholesterol. Lead scientist, Wilhelmina Kalt, Ph.D, from Agricul...

Research Presented at ISHLT Shows Promise of Addressing Critical Organ Shortage and Better Organ Preservation

BOSTON, April 10 /PRNewswire/ -- Data from experimental work on the use of organs from cardiac arrested donors will be presented this week at the International Society for Heart and Lung Transplantation's 28th Annual Meeting and Scientific Sessions. Utilizing donors after cardiac death (DCD), ...

Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports

IRVINE, Calif., March 26 /PRNewswire-FirstCall/ -- NuRx Pharmaceutical Inc.'s (OTC Bulletin Board: NURX) next-generation rexinoid agonist, NRX4204, significantly reduced the number and size of lung tumors and lowered the total tumor volume in mouse models compared to the control group, accordi...

Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)

Unique monoclonal antibody successfully targets human leukemic stem cells ATLANTA, Dec. 10 /PRNewswire/ -- CSL Limited, Australia's leading biopharmaceutical company, has today presented data at the American Society of Hematology (ASH) 49th annual meeting, which demonstrate the promising pre-cl...

Targeted Nanoparticles Offer Promise in the Battle Against Cancer

RESEARCH TRIANGLE PARK, N.C., Oct. 16 /PRNewswire/ -- Liquidia Technologies announces a series of speaking engagements by company founder and University of North Carolina-Chapel Hill professor, Joseph DeSimone. At a series of events this fall, Dr. DeSimone will discuss drug delivery applicatio...

Newly Approved HIV Drug Shows Great Promise

Pricing Level Should Improve Access WASHINGTON, Jan. 30 /PRNewswire/ -- The AIDS Institute, a national public policy research, advocacy, and education organization, is encouraged with the FDA's approval of the first new non-nucleoside reverse transcriptase inhibitor (NNRTI) i...

Data on Telavancin and Micafungin Hold Promise of New Therapeutic Options in Fight Against Serious Infectious Disease

- Studies Reinforce Astellas Commitment to Overcoming Critical Shortage of New Antimicrobial Agents MUNICH, Germany, April 02, 2007 /PRNewswire/ --Study results presented at the 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) show that the antibiotic telavancin, ...

Alzheimer's Drug Shows Promise in Fighting Cancer

LOS ANGELES, April 17, 2007 /PRNewswire/ -- Researchers from the Barbara Ann Karmanos Cancer Institute in Detroit, MI presented strong evidence today that an antibiotic typically prescribed for Alzheimer's patients could be effective in eventually treating certain types of cancers. Q. Ping Dou, ...

RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds Significant Promise for Treating Breast Cancer

IRVING, Texas--(BUSINESS WIRE)--May 15, 2007 - Reata Pharmaceuticals, Inc. today announced the publication of an article in the May 2007 issue of the journal Cancer Research showing that RTA 402, the company's Phase 2 development candidate for cancer, was highly effective in a rigorous animal model...

Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)

Phase II GBM study presented at ASCO with cediranib - a selective VEGF signaling inhibitor - shows over a quarter of patients alive and progression- free at six months(1) CHICAGO, June 04, 2007 /PRNewswire/ -- Data for the investigational agent cediranib (AZD2171) were presented today at the annua...

Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients

CHICAGO, DARMSTADT, Germany, June 5, 2007 – This year’s American Society of Clinical Oncology (ASCO) meeting in Chicago sees a wealth of promising new data presented regarding Merck KGaA’s targeted cancer therapy Erbitux® (cetuximab), further demonstrating the consistent effi...

Trial Results with Intranasal Fentanyl Hold Promise for Treatment of Breakthrough Pain in Cancer

BUDAPEST, Hungary, June, 7, 2007--A pioneering nasal spray could stop thousands of patients with cancer from suffering unnecessary pain; it was reported today1 at the 10th Congress of the European Association for Palliative Ca...

Anti-TNF Golimumab Continues to Show Promise in Phase II Rheumatoid Arthritis Study

Golimumab Demonstrated Sustained Improvement in Signs and Symptoms Of Moderate to Severe Rheumatoid Arthritis With One-Third of Patients Achieving Disease Remission at One-Year Mark BARCELONA, Spain, 14 June 2007 – One-year data show nearly 75 percent of patients with moderate to severe ...

Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections

DENVER--(BUSINESS WIRE)--Jul 2, 2007 - Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP), a biopharmaceutical company focused on infectious disease and dermatology, today announced that researchers at the University of Pennsylvania led by Dr. Paul Janmey and Dr. Robert Bucki, in collaboration with Dr. P...

New Drugs in Multinational Study Show Promise in Fighting Drug-Resistant HIV

Phase III clinical trial provides hope that HIV patients can live longer lives PASADENA, Calif., July 05, 2007 /PRNewswire/ -- A new investigational drug used in combination with a second newer agent has proven to be effective in fighting drug-resistant HIV, according to a Lancet article to be pub...

MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial

MARTINSRIED/MUNICH, Germany, July 9, 2007-A virus that has been specifically designed by scientists to be safe to normal tissue but deadly to cancer is showing early promise in a preliminary study, researchers said today at the ESMO Conference Lugano (ECLU), Switzerland. The virus, called NV1020...

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

...res and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, help...

Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis

...dy for presentation at an upcoming medical meeting. "The results of this study affirm BA058's safety and bone-building activity and support its promise as a next-generation anabolic treatment for osteoporosis," said C. Richard Lyttle, PhD, President and CEO of Radius. "We are especially encouraged by ...

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

...lops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helpi...

Economy is Driving Many Osteoporotic Women to Retire Later - But Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease

...ures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helpi...

BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza

...ing. "The clinical outcomes of these Phase 3 studies are important, especially during the declared influenza pandemic, as they indicate the promise of peramivir as a treatment for influenza," commented Dr. William P. Sheridan, Chief Medical Officer of BioCryst. "The need for additional anti-viral...

deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke

... DG071 and a platform for other PDE4 modulators with therapeutic applications in Alzheimer's disease and other conditions. deCODE is delivering on the promise of the new genetics(SM). Visit us on the web at http://www.decode.com ; on our diagnostics site at http://www.decodediagnostics.com ; for our pionee...

First Patient of NOTES Investigational Device Exemption (IDE) Study Successfully Treated With Ethicon Endo-Surgery Devices

...al step in advancing NOTES and NOTES specific technology, which holds great promise for improving surgery for both patients and physicians." The study, wh...important contributions in a growing body of evidence that demonstrates the promise of the Ethicon Endo-Surgery Toolbox for natural orifice surgery," said Kenn...

Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases

...re the importance of the RANK Ligand pathway in bone disease, and offer the promise of improved care for patients with advanced breast cancer. We look forward...nce 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, ...

USC Keck School of Medicine's Dr. Alan Epstein Receives Prestigious National Cancer Institute RAID Award for Breakthrough IL-2 Molecule Therapeutic

...opel the manufacturing of this novel molecule toward Phase 1 clinical trials." "We are in the midst of a biomedical revolution. New technologies promise to reshape medicine - with novel applications in new therapies, drug delivery, and patient care," said Dr. Richard Hull, Senior Director of Innovation...

New AHRQ Study Finds Mixed Evidence on Use of Radiofrequency Catheter Ablation for Treating Atrial Fibrillation

...there is little evidence indicating the procedure's effectiveness when used as a first-line therapy instead of medication. "Radiofrequency holds promise for treating atrial fibrillation, but it is clear that more research is needed to demonstrate its potential long-term benefits," said AHRQ Director Ca...

deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia

... cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and deCODE BreastCancer, for the common forms of breast cancer. deCODE is delivering on the promise of the new genetics.SM Visit us on the web at http://www.decode.com ; on our diagnostics site at http://www.decodediagnostics.com ; for our pioneeri...

Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs

...f drug discovery programs based on our investments in basic research. -FSMA has invested significant resources into alternative approaches that show promise to cure SMA. www.curesma.org ...

Glybera(TM) Shows Long-Term Health Benefits

...lidated a stable, scalable, commercially attractive and GMP-compliant AAV manufacturing platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases that are caused by one faulty gene. AMT currently has a product pipeline with nine products at different stage...

Value of Genetic Testing for Preventing Blood Clots Unproven, According to New AHRQ Study

...patients show that 258,000 individuals were diagnosed with the condition in 2006, and 20,000 died as a result. "While genetic testing shows great promise to improve treatment and prevent disease, this report clearly shows that we need more research and evidence to achieve its full potential," said AHRQ ...

When It Comes to Natural Remedies for Hormonal Balance, the Proof Is in the Clinical Research

...eased rates of breast cancer and stroke, (per JAMA 2002; 288:321-333.) causing American women to reject the drug en masse. While natural products that promise relief from menopausal symptoms abound, few have success rates higher than 50% and none have been clinically proven to regulate hormone levels; with o...

New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients

...een discontinued for all other reasons achieved ACR 20, compared with 20 percent of patients receiving placebo ( p =0.027). "Golimumab has shown promise in the treatment of rheumatoid arthritis patients who have previously discontinued other anti-TNF-alpha therapies," said Josef S. Smolen, MD, Professo...

Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis

...said Iain B. McInnes, MD, PhD, FRCP, Professor of Experimental Medicine, University of Glasgow , study investigator. "These findings demonstrate the promise and utility of golimumab in treating both the joint and skin manifestations of this disease." In the open-label, uncontrolled extension of the G...

VivoMetrics(R) Introduces Next Generation LifeShirt Prototype, a Smart Garment That Delivers Real-time Vital Signs Remotely to Healthcare Providers

...se in order for adoption to increase(2). VivoMetrics' intent is to address these needs with the next generation LifeShirt and help make the full promise of RPM a reality. "VivoMetrics has been a true innovator in remote monitoring technologies," says Kent Tonkin, assistant director of information...
Other Tags
(Date:8/20/2014)... , Aug. 20, 2014 /CNW/ -  Issue ... warning and can quickly become life threatening for some children. ... many as 1.2 million Canadians have food allergies and this ... per cent of children are estimated to have food allergies.  ... from mild skin irritations and hives to breathing difficulties and ...
(Date:8/20/2014)... University, the Wellcome Trust Sanger Institute and the Swiss ... Mycobacterium pinnipedii from skeletons found in Peru which ... a relative of the TB bacterium that affects seals ... researchers assume that seals carried the pathogens from Africa ... was unexpected" comments Sebastien Gagneux, from the Swiss Tropical ...
(Date:8/20/2014)... are visible in in this image of the Para ... these were most likely intentionally set in order to ... forest or stand of trees where the land is ... include conversion of forestland to farms, ranches, or urban ... green of the Amazon Rainforest in the middle of ...
Breaking Biology News(10 mins):Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3
(Date:8/20/2014)... PA (PRWEB) August 20, 2014 A ... products from the blood did not improve survival chances ... analysis led by experts at the University of ... published online today in the journal PLOS One ... standardly used for people with sudden kidney failure, may ...
(Date:8/20/2014)... The non-small cell lung cancer (NSCLC) market ... across the top 8 developed nations, from just over ... 8 billion by 2020-end, posting a CAGR of 6.6% ... be driven by innovative therapies entering the squamous cell ... unlike the non-squamous segment. Thus, patients with SCC are ...
(Date:8/20/2014)... (HealthDay News) -- New research reveals that, long ago, ... global spread of the infectious disease known as tuberculosis. ... Africa to seals and sea lions, who then spread ... ago, according to an international team of researchers. ... again worldwide. This study and further research will help ...
(Date:8/20/2014)... August 20, 2014 Caddis Partners LLC, ... of any healthcare real estate company in recent years, ... assets valued at $500 million, including more than $100 ... significant growth, including expansions into new geographic regions and ... company executives are pleased to announce an enhanced brand ...
(Date:8/20/2014)... August 20, 2014 Get the report ... with mergermarket presents ‚ÄúDeal Drivers 2014 Half Year Report ... of M&A activity in both North and South America, ... , About Merrill DataSite     , Merrill DataSite is a ... optimises the due diligence process by providing a highly ...
Breaking Medicine News(10 mins):Health News:Pitt Analysis Questions Use of Acute Hemodialysis Treatment 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 3Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 4Health News:Seals, Sea Lions Helped Global Spread of TB, Study Finds 2Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 2Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 3Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 4Health News:Register to Download Merrill DataSite's Report: Deal Drivers 2014 Half Year Report for the Americas 2
Other Contents